Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

被引：290

作者：

Akter, Kawser ^{[1
]}

Lanza, Emily A. ^{[1
]}

Martin, Stephen A. ^{[1
]}

Myronyuk, Natalie ^{[1
]}

Rua, Melanie ^{[1
]}

Raffa, Robert B. ^{[1
]}

机构：

[1] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 71卷 / 03期

关键词：

Alzheimer's disease; clinical trial; diabetes; insulin physiology; BLOOD-BRAIN-BARRIER; END-PRODUCTS AGES; GROWTH-FACTOR-I; MILD COGNITIVE IMPAIRMENT; ISLET AMYLOID POLYPEPTIDE; INSULIN-DEGRADING ENZYME; ACTIVATED RECEPTOR-GAMMA; CENTRAL-NERVOUS-SYSTEM; PROTEIN-TAU TAU; OXIDATIVE STRESS;

D O I：

10.1111/j.1365-2125.2010.03830.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epidemiological and basic science evidence suggest a possible shared pathophysiology between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). It has even been hypothesized that AD might be 'type 3 diabetes'. The present review summarizes some of the evidence for the possible link, putative biochemical pathways and ongoing clinical trials of antidiabetic drugs in AD patients. The primary and review literature were searched for articles published in peer-reviewed sources that were related to a putative connection between T2DM and AD. In addition, public sources of clinical trials were searched for the relevant information regarding the testing of antidiabetic drugs in AD patients. The evidence for a connection between T2DM and AD is based upon a variety of diverse studies, but definitive biochemical mechanisms remain unknown. Additional study is needed to prove the existence or the extent of a link between T2DM and AD, but sufficient evidence exists to warrant further study. Presently, AD patients might benefit from treatment with pharmacotherapy currently used to treat T2DM and clinical trials of such therapy are currently underway.

引用

页码：365 / 376

页数：12

共 161 条

[1] INSULIN-LIKE GROWTH FACTOR-I (IGF-1) RECEPTORS IN THE HUMAN-BRAIN - QUANTITATIVE AUTORADIOGRAPHIC LOCALIZATION [J].

ADEM, A ;

JOSSAN, SS ;

DARGY, R ;

GILLBERG, PG ;

NORDBERG, A ;

WINBLAD, B ;

SARA, V .

BRAIN RESEARCH, 1989, 503 (02) :299-303

[2] Inflammation and Alzheimer's disease [J].

Akiyama, H ;

Barger, S ;

Barnum, S ;

Bradt, B ;

Bauer, J ;

Cole, GM ;

Cooper, NR ;

Eikelenboom, P ;

Emmerling, M ;

Fiebich, BL ;

Finch, CE ;

Frautschy, S ;

Griffin, WST ;

Hampel, H ;

Hull, M ;

Landreth, G ;

Lue, LF ;

Mrak, R ;

Mackenzie, IR ;

McGeer, PL ;

O'Banion, MK ;

Pachter, J ;

Pasinetti, G ;

Plata-Salaman, C ;

Rogers, J ;

Rydel, R ;

Shen, Y ;

Streit, W ;

Strohmeyer, R ;

Tooyoma, I ;

Van Muiswinkel, FL ;

Veerhuis, R ;

Walker, D ;

Webster, S ;

Wegrzyniak, B ;

Wenk, G ;

Wyss-Coray, T .

NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421

[3] Diabetes mellitus and risk of developing Alzheimer disease - Results from the Framingham study [J].

Akomolafe, Abimbola ;

Beiser, Alexa ;

Meigs, Phdjames B. ;

Au, Rhoda ;

Green, Robert C. ;

Farrer, Lindsay A. ;

Wolf, Philip A. ;

Seshadri, Sudha .

ARCHIVES OF NEUROLOGY, 2006, 63 (11) :1551-1555

[4]

Alzheimer's Association, 2010, Alzheimers Dement, V6, P158, DOI 10.1016/j.jalz.2010.01.009

[5]

Ando K, 1999, J NEUROSCI, V19, P4421

[6]

[Anonymous], 2000, DSM 4 TR DIAGN STAT

[7]

[Anonymous], 1996, The pharmacological basis of therapeutics

[8]

[Anonymous], 2007, National Diabetes Fact Sheet

[9] Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists - The Cache County Study [J].

Anthony, JC ;

Breitner, JCS ;

Zandi, PP ;

Meyer, MR ;

Jurasova, I ;

Norton, MC ;

Stone, SV .

NEUROLOGY, 2000, 54 (11) :2066-2071

[10] Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin [J].

Banks, WA ;

Jaspan, JB ;

Kastin, AJ .

PEPTIDES, 1997, 18 (10) :1577-1584

← 1 2 3 4 5 6 7 8 9 10 →